Ensayos clínicos de leucemia

341 estudios buscan participantes en EE. UU.

La investigación sobre la leucemia se centra en ensayos de tratamiento de fases tempranas —fase 1 y fase 1/2— con medicamentos dirigidos y terapias celulares como CAR-T. La elegibilidad depende mucho del tipo de leucemia (por ejemplo, LMA, LLA o LLC), de los marcadores genéticos y de los tratamientos previos. Muchos estudios se realizan en grandes centros oncológicos, así que es posible que tenga que viajar.

Mostrando 40 de 341 estudios (en inglés)

RecruitingPhase 3NCT03150693

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Sponsor: Alliance for Clinical Trials in Oncology

Birmingham, AL · Anchorage, AK · +452 more sites

RecruitingPhase 2NCT06317662

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Sponsor: National Cancer Institute (NCI)

Birmingham, AL · Anchorage, AK · Mesa, AZ · +112 more sites

RecruitingPhase 1NCT06575296

Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant

Sponsor: City of Hope Medical Center

Duarte, CA

RecruitingPhase 1NCT06904066

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

Sponsor: National Cancer Institute (NCI)

Bethesda, MD

RecruitingPhase not listedNCT01087333

Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment

Sponsor: National Cancer Institute (NCI)

Bethesda, MD

RecruitingPhase 2NCT05554393

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Sponsor: National Cancer Institute (NCI)

Birmingham, AL · Tucson, AZ · +172 more sites

RecruitingPhase not listedNCT05588154

Collection of Blood, Bone Marrow, Skin, Saliva, and Stool Samples From Healthy Volunteers Used for Comparative Analysis of Myeloid Malignancies

Sponsor: National Cancer Institute (NCI)

Bethesda, MD

RecruitingPhase 1 / Phase 2NCT06364423

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias

Sponsor: National Cancer Institute (NCI)

Bethesda, MD

RecruitingPhase 1NCT06846606

Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS

Sponsor: Auron Therapeutics, Inc.

Duarte, CA · Tampa, FL · Buffalo, NY · +6 more sites

RecruitingPhase 1NCT04301076

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

Sponsor: National Cancer Institute (NCI)

Atlanta, GA · City of Saint Peters, MO · +16 more sites

RecruitingPhase 1NCT06528301

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

Sponsor: Umoja Biopharma

Duarte, CA · Chicago, IL · Grand Rapids, MI · +4 more sites

RecruitingPhase 1 / Phase 2NCT07109219

Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

Sponsor: AstraZeneca

Duarte, CA · Jacksonville, FL · Chicago, IL · +3 more sites

RecruitingPhase 1NCT07424833

A Study of APG-3288 in Relapsed/Refractory Blood Cancers

Sponsor: Ascentage Pharma Group Inc.

Los Angeles, CA · Jacksonville, FL · Grand Rapids, MI · +2 more sites

RecruitingPhase 1NCT07532525

Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma

Sponsor: University of Michigan Rogel Cancer Center

Ann Arbor, MI

RecruitingPhase 1NCT07723703

Phase 1 Open-label Study of AMX-883 Alone in Participants With AML and High-risk MDS and in Combination in Participants With AML

Sponsor: Amphista Therapeutics Ltd

Fairfax, VA

RecruitingPhase 1NCT05188170

Niclosamide in Pediatric Patients With Relapsed and Refractory AML

Sponsor: Stanford University

Palo Alto, CA

RecruitingPhase 2NCT06128070

Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

Sponsor: City of Hope Medical Center

Duarte, CA

RecruitingPhase 2NCT06317649

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Sponsor: National Cancer Institute (NCI)

Birmingham, AL · Tucson, AZ · +222 more sites

RecruitingPhase 1NCT02390635

PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia

Sponsor: M.D. Anderson Cancer Center

Houston, TX

RecruitingPhase not listedNCT04028531

Understanding Chronic Lymphocytic Leukemia

Sponsor: Dana-Farber Cancer Institute

Boston, MA

RecruitingPhase not listedNCT05724121

Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax

Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Bethesda, MD

RecruitingPhase 3NCT06136559

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

Sponsor: Merck Sharp & Dohme LLC

Mobile, AL · Gilbert, AZ · Phoenix, AZ · +46 more sites

RecruitingPhase 1 / Phase 2NCT06137118

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

Sponsor: AstraZeneca

Birmingham, AL · Duarte, CA · Los Angeles, CA · +9 more sites

RecruitingPhase 2NCT06236724

Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.

Sponsor: M.D. Anderson Cancer Center

Houston, TX

RecruitingPhase 2NCT06672146

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

Sponsor: National Cancer Institute (NCI)

Tucson, AZ · Little Rock, AR · +132 more sites

RecruitingPhase 3NCT07007312

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Sponsor: Kura Oncology, Inc.

Gilbert, AZ · Clovis, CA · La Jolla, CA · +41 more sites

RecruitingPhase 2NCT07269470

Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

Sponsor: M.D. Anderson Cancer Center

Houston, TX

RecruitingPhase not listedNCT03854318

Longitudinal Studies of Patient With FPDMM

Sponsor: National Human Genome Research Institute (NHGRI)

Bethesda, MD

RecruitingPhase 1 / Phase 2NCT04065399

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Sponsor: Syndax Pharmaceuticals

Duarte, CA · Los Angeles, CA · Palo Alto, CA · +19 more sites

RecruitingPhase 1NCT05010772

Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission

Sponsor: M.D. Anderson Cancer Center

Houston, TX

RecruitingPhase 2NCT06315309

Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant

Sponsor: University of Alabama at Birmingham

Birmingham, AL

RecruitingPhase 1 / Phase 2NCT07128381

Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)

Sponsor: M.D. Anderson Cancer Center

Houston, TX

RecruitingPhase not listedNCT07313592

Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients

Sponsor: Washington University School of Medicine

St Louis, MO

RecruitingPhase 1NCT07388563

Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

Sponsor: National Cancer Institute (NCI)

Bethesda, MD

RecruitingPhase 2NCT00501826

Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Sponsor: M.D. Anderson Cancer Center

Houston, TX

RecruitingPhase 2NCT05672251

Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Sponsor: City of Hope Medical Center

Duarte, CA

RecruitingPhase 1 / Phase 2NCT06129734

Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant

Sponsor: Benjamin Tomlinson

Cleveland, OH

RecruitingPhase 2NCT07060001

Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker

Sponsor: The Methodist Hospital Research Institute

Houston, TX

RecruitingPhase 1NCT07751991

A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML

Sponsor: Charm Therapeutics

Duarte, CA · New Haven, CT · Grand Rapids, MI

RecruitingPhase 2NCT00801489

Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Sponsor: M.D. Anderson Cancer Center

Houston, TX

Ver esta página en inglés

La información proviene de ClinicalTrials.gov y es solo informativa; no es consejo médico. Confirme siempre su elegibilidad con el equipo del estudio y hable con su médico antes de tomar decisiones sobre su atención.